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Abstract
Nuvaring (Organon, Kenilworth, NJ) is a vaginal contraception ring inserted by the patient. It was approved by the Food and Drug Administration in 2001
for the prevention of pregnancy. The intent of this paper is to increase the awareness of Nuvaring among plastic surgeons, and to explore the risks associated
with its use. We report the cases of two cosmetic surgery patients. These patients developed deep venous thrombosis and pulmonary emboli in the postop-
erative period while using Nuvaring. The very advantages of the Nuvaring—the ease of use, the avoidance of daily administration, and the insertion and
removal of the device by the patient—may lead to the failure of patients to recollect being on a vaginal ring for contraception.
Level of Evidence: 4
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It is a common clinical scenario for an aesthetic plastic
surgeon to treat a female patient seeking cosmetic surgery
who is taking some form of contraception. In 2010, 62 million
US women were in their child-bearing years (15–44) and 70%
were at risk of unintended pregnancy.1 In 2010, 2.2% of all
contraceptive users in the US (830 000 of 61 million) used a
vaginal ring as their method.1 It is imperative that the plastic
surgeon both uncover the use of contraceptives in their preop-
erative evaluation and have the patient stop contraceptives for
at least 4 weeks before surgery. The surgeon can also advise
the patient to seek alternative means of contraception
(condoms, etc.) for both before and after surgery. The manu-
facturer’s recommendation for Nuvaring, a vaginal ring, is to
cease its use for at least 4 weeks before surgery and to not
restart it until at least 2 weeks after surgery, as per the
package insert Warnings and Precautions section (Merck &
Co, Inc, last revised 11/2014). The purpose of stopping the
oral contraceptive use before surgery is to avoid the increased
risk of venous thromboembolism (VTE) among contraceptive
users in the perioperative period.2-4
Nuvaring (Organon, Kenilworth, NJ) is a vaginal contra-
ception ring approved by the Food and Drug Administration
in 2001 for the indication of prevention of pregnancy. It is a
non-biodegradable, latex-free, ﬂexible, transparent, combined
contraceptive vaginal ring.5 The ring must be inserted by the
patient in the vagina on or before day ﬁve of the menstrual
cycle. Each ring is worn for 3 weeks, followed by a 1 week in-
terval without the ring.6 After 7 days, the patient inserts a
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new ring. Each ring contains 2.7 mg of ethinylestradiol (EE)
and 11.7 mg of etonogestrel, and releases on average 0.015
mg/day of EE and 0.120 mg/day of etonogestrel over a 3
week period of use.5,7 Etonogestrel is the active metabolite of
desogestrel, a third-generation progestin and common com-
ponent of oral contraceptive medications. It is the progestin
component of oral contraceptives that have beenmost recently
implicated in the increased risk of venous thromboembo-
lism.2,8,9,10 Studies published in 1995 and 1996 demonstrated
that third-generation progestins (desogestrel and etonoges-
trel) were associated with a higher risk of venous thrombo-
sis in comparison to the older progestins (levonorgestrel
and norgestrel).2,8,9,10 One study reported that the use of
third-generation oral contraceptives was associated with a
four-fold increase in the risk of venous thromboembolism
compared to users of second-generation oral contraceptives,
particularly among young, healthy women.3,11
The vaginal ring’s steady release of the EE and etonoges-
trel allows for continuous absorption through the vaginal
epithelium. The systemic exposure to EE, the estrogen com-
ponent, with the vaginal ring is about half the exposure to
EE with the third-generation oral contraceptives.12 The
pharmacokinetics of etonogestrel, the progestin component
in the vaginal ring, are different in comparison to oral con-
traceptives, with a lower overall dose given but a higher ab-
solute bioavailability leading to a similar systemic exposure
for both modalities of administration.13
The potential advantages of the vaginal ring in compari-
son to oral contraceptives include: ease of use and conve-
nience; avoidance of daily administration, resulting in higher
compliance and more effective contraception; constant
lower plasma concentrations of the drugs; avoidance of gas-
trointestinal and hepatic ﬁrst-pass metabolism; and insertion
and removal of the device by the patient. In comparison to
oral contraceptives, Nuvaring has been reported in the litera-
ture to offer better cycle control and a higher likelihood to
continue with the contraceptive once using it.14
Despite these proven and potential advantages, Nuvaring
is relatively new and data about its adverse effects are
limited. Two cases of cerebral venous sinus thrombosis in
healthy patients on Nuvaring, a relatively rare clinical entity,
have been reported in the literature.15,16 A recent New
England Journal of Medicine article suggested a higher ad-
justed relative risk of thrombotic stroke in patients who used
a vaginal ring or a transdermal patch in comparison to pa-
tients on oral contraceptives. Although the higher adjusted
relative risks were statistically indistinguishable and the con-
ﬁdence intervals overlapped, the authors went on to suggest
that one might expect a higher risk of thrombotic stroke with
parenteral administration than with oral administration of
combined oral contraceptives.17
Nuvaring, designed to deliver a lower dose of hormones in
comparison to oral contraceptives, is hypothesized to lower
the risk of venous thrombosis due to the lower exposure to
hormones. Although the data is still limited, recent studies
have begun to call this hypothesis into question. One study
found higher levels of activated protein C resistance and sex
hormone-binding globulin—both measures associated with
an increased risk of venous thrombosis—in patients on the
vaginal ring in comparison to those on second-generation
oral contraceptives.18 The authors went on to state that third-
generation combined contraceptives have a higher pro-
thrombotic effect than second-generation ones, independent
of the route of administration.18 Five cases of deep vein
thrombosis (DVT) associated with Nuvaring have been re-
ported in the literature.19-23 These reported cases were in
healthy patients on Nuvaring with no other risk factors for
DVT and no recent surgeries. We report two cosmetic surgery
patients from two different surgeons who developed DVTs
and pulmonary emboli in the postoperative period while
taking Nuvaring.
CASE 1
A healthy 26-year-old African-American female presented
to the ﬁrst surgeon’s clinic in May 2011 for breast aug-
mentation. Her medical and surgical history was only
notable for asthma, for which she was not on any medica-
tions. The patient denied a history of VTE or cancer or any
recent immobility, trauma, surgery, pregnancy, or miscar-
riages. She also denied taking any medications or contra-
ceptives, both on the patient intake form as well as in the
patient interview. She reported no drug allergies or any
history of smoking, alcohol, or illicit drug use. She reported
no family history of any diseases or hypercoagulation disor-
ders. There were no clinical abnormalities on physical
examination. The patient had a pre-treatment history and
physical examination and pre-treatment clearance by her
primary care doctor, as well as pre-treatment labs [com-
plete blood count (CBC), Chem-7, prothrombin time/
partial thromboplastin time (PT/PTT), urine pregnancy
test, and EKG] that were all normal. She was scheduled for
a bilateral breast augmentation.
Given the patient’s absence of known risk factors for
DVT, she was assessed as moderate risk for DVT because of
the 1 hour surgery planned, and intermittent pneumatic
compression stockings were used for DVT prophylaxis. She
underwent placement of bilateral, subglandular, smooth,
round-proﬁle silicone gel implants (286 cc Allergan style
15) under general anesthesia. The surgery was uneventful.
The patient was seen on postoperative day 2 and was doing
well and had no complaints. On postoperative day 12, the
patient contacted the ofﬁce because of right-sided chest
pain. The patient was brought back to the clinic for imme-
diate evaluation. The patient did report a history of right-
sided calf pain that presented on postoperative day 2 and
spontaneously resolved two days later. She now described
deep right-sided chest pain, which worsened with full
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inspiration. Her vital signs were a pulse of 100, respiratory
rate of 20%, and 100% saturation on room air on pulse ox-
imetry. She had good breath sounds bilaterally on ausculta-
tion. Examination of the lower extremities did not reveal
any signiﬁcant swelling, cyanosis, or calf tenderness, and
bilateral Homan’s signs were negative.
The patient was transferred via ambulance to the emer-
gency department for workup for a suspected pulmonary
embolism. Initial labs with coagulation proﬁle (PT, PTT) and
CBC were normal. A chest x-ray done in the emergency
department was unremarkable. A spiral CT scan revealed
bilateral pleural effusions and ﬁlling defects in segmental
branches of the pulmonary artery in the left upper and lower
lobes and the right lower lobe, consistent with bilateral
pulmonary emboli (Figure 1). The spiral CT scan also dem-
onstrated a deep venous thrombosis in the distal right super-
ﬁcial femoral vein, popliteal vein, and veins of the right calf
(Figure 1).
The patient was admitted to the medical service for man-
agement of pulmonary emboli and deep venous thrombosis.
She was started on therapeutic enoxaparin (90 mg) subcuta-
neously daily and then, a day later, began a daily warfarin
regimen. After discovering that the patient was on Nuvaring
implantable contraception, it was stopped. During the
hospitalization, a workup for hypercoagulability disorders,
including Factor V, was negative. She was discharged on
hospital day 3 on an anti-coagulant program, with instruc-
tions to follow up with hematology. The patient completed
5 months of warfarin therapy and was advised to perma-
nently avoid hormonal-based contraceptives. She was seen
in follow-up at just over 7 months postoperative, when she
was free of symptoms and doing well from an aesthetic
standpoint.
CASE 2
A healthy 29-year-old non-smoking Caucasian female pre-
sented to the second surgeon’s ofﬁce in June 2011 for an
abdominoplasty. The patient’s past medical history was sig-
niﬁcant for non-Hodgkin’s lymphoma of the chest, diagnosed
8 years prior and treated with chemotherapy. She had been
free of disease for 5 years. The patient denied a history of
VTE or any recent immobility, trauma, surgery, pregnancy,
or miscarriages. She also denied taking any medications or
contraceptives on both the patient intake form as well as in
the patient interview. She reported no drug allergies or any
history of smoking, alcohol, or illicit drug use. She reported
no family history of any diseases or hypercoagulation
Figure 1. CT images of the chest and lower extremities of a 26-year-old woman demonstrating the following: (A) left lower lobe
pulmonary embolus as denoted by the arrow, (B) right lower lobe pulmonary embolus as denoted by the arrow, (C) left upper lobe
pulmonary embolus as denoted by the arrow, and (D) deep vein thrombosis (DVT) of the right distal superﬁcial femoral vein.
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disorders. The patient had a preoperative history and physi-
cal examination and preoperative clearance by her primary
care doctor, as well as preoperative labs (CBC, Chem-7,
PT/PTT, Urine Pregancy, EKG) that were all normal.
The patient underwent an abdominoplasty without plica-
tion for 3 hours under epidural anesthesia without any com-
plications, and was discharged to home on the day of surgery.
Intermittent pneumatic compression devices and elastic
stockings were used for DVT prophylaxis during the surgery.
On postoperative day 5, the patient presented via ambu-
lance to the emergency department in no acute distress but
complaining of increased weakness, fatigue, and dizziness.
She also noted palpitations and chest discomfort but no
shortness of breath. She was tachycardic (120 beats/
seconds) and mildly hypotensive (90/55), but had a pulse
oximetry saturation of 95% on room air. She had bilateral
breath sounds, and examination of her lower extremities
was normal.
The patient was given maintenance intravenous ﬂuids and
boluses for her suspected dehydration from poor oral intake in
the relatively immediate postoperative period. A 12-lead elec-
trocardiogram demonstrated sinus tachycardia with a T-wave
abnormality. Lab work was essentially normal, except for a
slightly elevated white blood cell count of 12.2 and mild
anemia with a Hemoblobin of 9.6 and a Hematocrit of 27.7.
There was strong consideration for pulmonary embolism
given her clinical presentation and the recent abdominoplasty.
CT angiography of the chest was ordered, which con-
ﬁrmed massive bilateral pulmonary emboli with involve-
ment of segmental and subsegmental branches of the
pulmonary artery system, as well as dependent bibasilar atel-
ectasis (Figure 2). Evidence on the CT scan of slight bowing
of the interventricular septum was noted, which suggested
right heart strain. The abdomen and pelvis were negative on
the scan, except for the presence of a contraceptive ring
device in the upper vagina and a small amount of pelvic
ascites. No evidence of any obvious deep venous thrombosis
was detected on the CT scan.
The patient was questioned about the contraceptive ring
device, and disclosed at this time that she was on a Nuvaring
contraceptive device at the time of the surgery, and had
been on the device for some time. According to the patient,
she had denied any medications in all of her preoperative
workup because she forgot she was on Nuvaring. After the
diagnosis of pulmonary embolism was conﬁrmed, weight-
based heparin therapy was started with a bolus and mainte-
nance drip. Vascular surgery was consulted for a potential
embolectomy, and the patient was admitted to the intensive
care unit.
Transthoracic echocardiography was performed and
showed normal left ventricle size and function, but a dilated
right ventricle with moderately reduced right ventricular
function. The echocardiogram also revealed evidence of sys-
tolic pulmonary hypertension. Venous dopplers of bilateral
lower extremities were also done and showed a deep venous
thrombosis in the left common femoral vein.
Vascular surgery was recommended for therapeutic
beneﬁt as well as to minimize possible future complications
such as pulmonary hypertension and right heart strain. On
hospital day 2, the patient received a pulmonary angiogra-
phy with catheter embolectomy of bilateral pulmonary
emboli using the AngioJet Xpeedior system (Bayer
HealthCare, Indianola, PA). An angiogram demonstrated a
ﬁlling defect of the right main pulmonary artery and the left
pulmonary artery supplying the lower lobe (Figure 3). An
embolectomy was done with full resolution of the clot in
the right main pulmonary artery and a majority resolution
in the left pulmonary artery.
The patient recovered and heparin therapy was transi-
tioned to enoxaparin (65 mg subcutaneous every 12 hours)
and warfarin. She was maintained on enoxaparin until ade-
quate anticoagulation could be achieved with the warfarin
regimen. During her hospital course, she remained stable
with normalization of her tachycardia and she was dis-
charged on warfarin with a therapeutic international normal-
ized ratio (INR) level on hospital day 8, with instructions for
follow-up. No primary hypercoaguability disorders were de-
tected on hematologic workup as an outpatient. The patient
completed a 6 month course of warfarin, and had no further
incidents related to the pulmonary embolism. She was ad-
vised to avoid all hormonally-based birth control methods.
DISCUSSION
We have reported two cases of VTE in patients who were on
Nuvaring and did not disclose that fact to the operating
Figure 2. CT angiography of the chest image of a 29-year-old
woman demonstrating bilateral pulmonary emboli in both
main pulmonary arteries (PA).
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surgeons before their cosmetic surgeries. In both cases, the
patients denied taking any medications, both on their
patient intake forms as well as in their patient interviews.
The very advantages of the Nuvaring—the ease of use, the
avoidance of daily administration, and the insertion and
removal of the device by the patient—may be the very
reason that leads to the failure of patients to disclose being
on a vaginal ring for contraception. Patients may not consid-
er that a vaginal ring is a medication that needs to be report-
ed to the physician. Given the fact that the patient
population that has cosmetic surgery often uses some form
of contraception, plastic surgeons may encounter more pa-
tients using Nuvaring in the future. It is imperative that
plastic surgeons are aware of the existence of the Nuvaring
device so that they can determine if a patient is using it and
discontinue its use before surgery. Plastic surgeons should
speciﬁcally ask patients if they are using a vaginal ring in
their risk evaluation for VTE.
Venous thrombembolism is a signiﬁcant source of post-
operative morbidity and mortality in postoperative surgical
patients. A British Medical Journal study points out a 10
time increased risk of VTE in female middle-aged women
having day surgery than those not having surgery. This risk
increases to 70 times more likely in patients having inpa-
tient surgery and persists for up to 12 weeks after surgery.4
None of the ﬁve cases of DVT associated with Nuvaring re-
ported in the literature were in postoperative patients.19-23
Clearly, both of the patients reported above were at in-
creased risk just from having surgery, but the degree of the
additional risk that can be attributed to Nuvaring in these
cases is unknown.
To explore the question of the additional risk attributed to
the Nuvaring, we retrospectively assessed each patient’s pre-
operative risk for VTE using the Caprini risk score. The
Caprini risk scoring system takes into account most known
risk factors for the development of VTE and assigns each
patient a score based on the presence or absence of these
factors.24 The largest study demonstrating the value of the
Caprini risk scoring system involved 8216 surgical patients as
part of the National Surgical Quality Improvement Program.25
The authors classiﬁed the patients into four groups, based on
their assessment scores, and calculated the associated inci-
dence of VTE: a low risk score of 0–1 corresponded to a VTE
incidence of 0%; moderate risk score of 2 to a VTE incidence
of 0.7%; a high risk score of 3–4 with a VTE incidence of
0.97%; and the highest risk score of 5–9+ with a VTE inci-
dence of 1.33–6.51%. As expected, the incidence of VTE
increased as the risk score increased.25 In terms of references
speciﬁc to the plastic surgery population, the Venous
Thromboembolism Prevention Study (VTEPS) is the largest
study to date that examines a risk-stratiﬁed approach to che-
moprophylaxis. A recent publication based on the VTEPS
data demonstrated that the 2005 Caprini Risk Assessment
Model provided superior risk stratiﬁcation in comparison to
the 2010 Model.26
The Caprini scoring system adds one point to the patient’s
overall risk score for VTE for the use of oral contraceptives or
hormone replacement therapy, and two to ﬁve points for
major surgery, depending on the length of the surgery.
These two risk factors alone can place a patient into the
high-risk category for VTE. Some plastic surgeons consider
having an abdominoplasty as a separate risk factor, assigning
it ﬁve points in the Caprini scoring system and automatically
elevating those patients to a high-risk category, indicating
the need for chemoprophylaxis in those patients.27 Using the
Caprini scoring system, the patient in case 1 would have
been classiﬁed as high risk based on her pretreatment risk
score of three: one point for the use of contraceptives and
two points for the 1 hour major surgery. With the non-
disclosure of the use of the Nuvaring, the patient’s risk score
decreased to two, putting her in the moderate risk category.
Intermittent pneumatic compression stockings were used for
VTE prophylaxis given the patient’s moderate risk assess-
ment. With better awareness of the Nuvaring, the operating
surgeon may have been able to elicit the presence of the
vaginal ring in the patient, discontinue its use, and place the
patient on the appropriate chemoprophylaxis regimen for
VTE prevention given her high-risk assessment.
As mentioned above, the Caprini risk assessment assesses
one point for the use of oral contraceptives or hormone
replacement therapy when calculating a risk score. Does
Nuvaring pose the same risk for VTE in surgical patients as
third-generation oral contraceptives, or is there an increased
Figure 3. Intraoperative pulmonary angiography of a
29-year-old woman with resolution of the pulmonary artery
ﬁlling defects after catheter embolectomy of bilateral pulmo-
nary emboli using the AngioJet Xpeedior system.
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risk? Should the risk assessment be different for Nuvaring?
The answer to these questions are unknown, but two
studies mentioned in the introduction have suggested an
increased risk of thrombotic stroke and increased levels of
activated protein C resistance with Nuvaring in comparison
to oral contraceptives.17,18 It is also important to note that
these are the ﬁrst two reported cases of VTE in postoperative
patients on Nuvaring. All of the previously-reported cases of
VTE in patients on Nuvaring have been in non-surgical pa-
tients. No data are available about the risk of venous throm-
bosis of the vaginal ring in comparison to third-generation
oral contraceptives. Given the fact that a large portion of pa-
tients having plastic surgery are candidates for Nuvaring,
further studies are needed to explore these questions.
In case 2, the patient was already at the highest risk of
VTE according to the Caprini risk assessment, but was not
given chemoprophylaxis by the operating surgeons. The
patient had a major surgery lasting 3 hours (three points), a
history of previous malignancy (two points), and was on a
Nuvaring at the time of surgery (one point). This gives the
patient a total risk score of six, placing her in the highest
risk class for VTE. The operating surgeons decided not to
use chemoprophylaxis in this case because it was done
under epidural anesthesia. The Caprini risk assessment
does not specify whether or not the ongoing use of contra-
ceptives during surgery constitutes an increased risk for
VTE. It also only includes the use of oral contraceptives in
its risk assessment score, not vaginal rings or transdermal
patches. As we learn more about the effects of Nuvaring,
the risk assessment may need to be adjusted to account for
nuances speciﬁc to the vaginal ring.
The pharmacokinetics of the vaginal ring are different in
two important ways that may pose an increased risk for
VTE. The ﬁrst difference, as mentioned in the introduction,
is avoidance of gastrointestinal and hepatic ﬁrst-pass metab-
olism. It does seem anatomically plausible that a venous
system exposed to the drainage from the vaginal epithelium
would have higher serum levels of hormone exposure before
it reaches the liver, increasing the potential for VTE. The
second difference is the maintenance of constant serum
levels of hormones. A noted in the paper by van den Heuvel
et al,13 the hormone serum levels have very little variation
with the vaginal ring. The oral contraceptives have more var-
iability, with more peaks and troughs in their serum levels.
The constant serum levels of patients on the vaginal ring are
higher than the trough serum levels of the patients on oral
contraceptives. This leads to a more constant higher expo-
sure to hormones.12 We point out these pharmacokinetic dif-
ferences between the two modalities of treatment but have
no data as to the clinical implications of these differences.
In case 2, the Nuvaring was discovered only after the
patient developed a VTE and the vaginal ring was seen on
the CT scan. If the patient in case 2 had disclosed the use of
a Nuvaring before surgery, the surgery could have been
delayed for 3–4 weeks to allow the patient to discontinue
use of the vaginal ring. The question remains whether
Nuvaring should be restarted 2 weeks after surgery if the
patient is ambulatory, as is recommended with oral contra-
ceptives. The recommendations and risk assessments
related to the Nuvaring have been given under the premise
that they are the same as oral contraceptives. The authors
of this paper question this premise until further studies
explore the true risks related to the use of the Nuvaring in
surgical patients. This study is limited by its small patient
population of two and is not intended to provide statistical
evidence in regards to the risks of vaginal rings. It is the
intent of the authors to educate the plastic surgery commu-
nity about vaginal rings and to begin further studies into
the potential VTE risks associated with their use.
CONCLUSION
We report two cases of venous thromboembolism in patients
having aesthetic surgery while on Nuvaring. The authors
recommend that until the exact potential risk of VTE associ-
ated with Nuvaring is elucidated, surgeons should speciﬁ-
cally query aesthetic surgery patients as to its use and
discontinue its use from 4 weeks preoperatively to 2 weeks
postoperatively.
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